Study on Efficacy and Safety of Bortezomib in Combination with Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma

摘要

Objective:To investigate the clinical effects of combining bortezomib with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.Methods:This study was conducted in Shaanxi Provincial People’s Hospital from January 2020 to January 2022.25 patients were selected for the study and divided into two groups:12 patients in one group,the control group,were treated with bortezomib and thalidomide in combination with dexamethasone,and 13 patients in the other group were treated with bortezomib and dexamethasone.The other group of 13 patients,given bortezomib combined with lenalidomide and dexamethasone,was named as the experimental group,and the treatment effects of the two groups were compared and analyzed.Results:Comparing the treatment efficiency of the two groups,the incidence of patients in the experimental group was 92.31%,which was significantly higher than that of the control group(33.33%),with a significant difference,indicated as P<0.05.At the same time,the incidence of adverse reactions in the experimental group was lower,the clinical index scores were closer to normal values,and the level of inflammatory response was lower,with significant differences in all data in the control group(P<0.05),and the experimental group had better treatment results.Conclusion:Bortezomib combined with lenalidomide and dexamethasone is clinically effective in the treatment of newly diagnosed patients with multiple myeloma,and is of positive significance in promoting recovery.